#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Idiopathic thrombocytopenia refractery to therapy of cyclosporine A in clinical practice – case report


Authors: Lucia Schwarzová;  Zdenko Pirník;  Natália Štecová
Published in the journal: Čes. slov. Farm., 2017; 66, 233-237
Category: Kazuistika

Summary

Primary immune thrombocytopenia (idiopathic thrombocytopenic purpura; ITP) is an autoimmune disorder characterized by isolated thrombocytopenia without abnormalities in the erythroid and myeloid/lymphoid lineages. The incidence of ITP in adults is estimated at approximately 1.6–3.9 per 100 000 persons/year. The aim of this study was to analyze a case report of a patient with diagnosed immune thrombocytopenia (D69.3) resistant to cyclosporine A therapy as well as an evaluation of factors that could contribute to an inadequate response to cyclosporine A. The results show a multifactorial origin of thrombocytopenia and a possible effect on refractivity to cyclosporine A therapy caused by long-term smoking, MDR-1 gene polymorphism, genetic predisposition to autoimmune diseases, allergic reactions as a manifestation of hypersensitivity in the immune system, controversial compliance of the patient, overcome infections as well as impact of drugs taken.

Key words:
immune thrombocytopeniarefractery formcyclosporine A therapy platelets


Zdroje

1. Lakshmanan S., Cuker A. Contemporary management of primary immune thrombocytopenia in adults. Journal of Thrombosis and Haemostasis 2012; 10, 1988–1998.

2. Cines D. B., et al. The Handbook First Edition. Immune thrombocytopenia. European School of Haematology 2011.

3. Penka M., a kol. Neonkologická hematologie. Praha: Grada Publishing 2009.

4. Mizutani H., et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice. Blood 1992; 79, 942–947.

5. Kahan B. D. Cyclosporine. The New England Journal of Medicine 1989; 321, 1725–1738.

6. Emilia G., et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99, 1482–1485.

7. Vyse T. J., Todd J. A. Genetic analysis of autoimmune disease. Cell 1996; 85, 311–318.

8. Shiozaki H., et al. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95, 2187–2188.

9. Gesundheit B., et al. Cyclosporin A in the treatment of refractory immune thrombocytopenic purpura in children. European Journal of Haematology 2001; 66, 347–351.

10. Neylon A. J., et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patient. British Journal of Haematology 2003; 122, 966–974.

11. Simanek R., et al. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Annals of Hematology 2007; 86, 705–710.

12. Khawandanah M. O., et al. Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device. Transfusion 2015; 55, 657–660.

13. Súhrn charakteristických vlastností lieku. Equoral 100 mg. Štátny ústav pre kontrolu liečiv. Dostupné z: https://www.adcc.sk/web/humanne-lieky/spc/equoral-100-mg-spc-6549.html

14. Súhrn charakteristických vlastností lieku. Sandimmun Neoral. 100mg. Státní ústav pro kontrolu léčiv. http://www.sukl.cz/modules/medication/detail.php?code=0015641&tab=texts

15. Tesfaye H., et al. Cyclosporine use in miscellaneous clinical settings other than organ transplantations: Is there any evidence for target levels? Annals of Transplantation 2008; 13, 34–40.

16. Choi P. Y., et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 2015; 126, 500–503.

17. Pasquale D., et al. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. American Journal of Hematology 1998; 57, 57–61.

18. Souček M., a kol. Vnitřní lékařství. 1. díl. Praha: Grada Publishing 2011.

19. Provan, D., Newland A. C. Current Management of Primary Immune Thrombocytopenia. Advances in therapy 2015; 32, 875–887.

20. Choudhary D. R., et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008; 93, e61.

21. Daniel F., et al. Multidrug Resistance Gene-1 Polymorphisms and Resistance to Cyclosporine A in Patients with Steroid Resistant Ulcerative Colitis. Inflammatory Bowel Disease 2007; 13, 19–23.

22. Sipeky C., et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug metabolism and Pharmacokinetics 2011; 26, 206–215.

23. Abrams C.S., et al. Thrombocytopenia. Goldman’s Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders 2016.

24. Agarwal A., et al. Fluconazole-induced thrombocytopenia. Annals of Internal Medicine 1990; 113, 899.

25. Bemt V. D., et al. Drug-induced immune thrombocytopenia. Drug Safety 2004; 27, 1243–1252.

26. Buck M. L. Drug-induced Thrombocytopenia. Pediatric Cases from the Medical Literature. Pediatric Pharmacology 2010; 16, 1–4.

27. Visentin G. P., Liu C. Y. Drug induced Thrombocytopenia. Hematology/Oncology Clinics of North America 2007; 21, 685–693.

28. Bangia A. V., et al. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian Journal of Pharmacology 2011; 43, 76–77.

29. Royer B., et al. Methylprednisolone-induced immune thrombocytopenia. Blood 2010; 115, 5431–5432.

30. Ahmed I., et al. Heparin induced thrombocytopenia: diagnosis and management update. Postgraduate Medical Journal 2007; 83, 575–582.

31. Reese J. A., et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116, 2127–2133.

32. Grosbois B., et al. Thrombocytopenia induced by angiotensin converting enzyme inhibitors. British Journal of Medicine 1989; 298, 189–190.

33. Teh C, McKendrick M. Ciprofloxacin-induced thrombocytopenia. Journal of Infection and Chemotherapy 1993; 27, 213–215.

34. Hasan A., et al. Treatment with rituximab in chronic ITP patients induces long-lasting responses in approximately 30% of patients but even these patients may relapse. Repeated Courses of Rituximab in Chronic ITP: Three Different Regimens. American Journal of Hematology 2009; 84, 661–665.

35. Cooper N., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology 2004; 125, 232–239.

Štítky
Farmacie Farmakologie

Článek vyšel v časopise

Česká a slovenská farmacie

Číslo 5

2017 Číslo 5
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

BONE ACADEMY 2025
nový kurz
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Vliv funkčního chrupu na paměť a učení
Autoři: doc. MUDr. Hana Hubálková, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#